CompletedPhase 1NCT02658981
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Principal Investigator
- Micheal Lim, MD, MDJohns Hopkins/ABTC
- Intervention
- Anti-LAG-3 Monoclonal Antibody BMS 986016(biological)
- Enrollment
- 63 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2023
Study locations (11)
- UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
- Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
- Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Collaborators
National Cancer Institute (NCI) · Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02658981 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05363826Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®Photolitec LLC